Bristol-Myers Squibb Company
COMBINATION OF A TETANUS TOXOID, ANTI-OX40 ANTIBODY AND/OR ANTI-PD-1 ANTIBODY TO TREAT TUMORS

Abstract:

Provided are methods for clinical treatment of cancers or tumors (e.g., advanced solid tumors) using (i) a combination of a tetanus toxoid, anti-OX40 antibody and anti-PD-1 antibody, (ii) a combination of anti-OX40 antibody and anti-PD-1 antibody, (iii) a combination of a tetanus toxoid and anti-PD-1 antibody, or (iv) an anti-PD-1 antibody.